Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group.
Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group.
复制标题
使用 CA-125 预测卵巢癌患者的生存率。
DOI：
--
复制
发表时间：
1989
影响因子：
45.3
通讯作者：
K. Bagshawe
中科院分区：
文献类型：
--
作者：
G. Rustin;J. Gennings;A. Nelstrop;H. Covarrubias;H. Lambert;K. Bagshawe
在54例晚期卵巢腺癌患者中评估血清CA-125测量的预后价值。作为北泰晤士合作组试验的一部分，所有患者都接受了至少两个疗程的卡铂治疗。经过至少6个月的随访，37名患者（69%）出现疾病进展的临床证据，其中28人死亡。化疗前CA-125的绝对水平在预测哪些患者将发展为疾病进展方面没有价值。然而，CA-125水平的变化从化疗前到1个月后，一个疗程的卡铂，可以用来划分患者的不同预后组。通过将患者分为CA-125水平下降超过7倍的患者和变化较小的患者，发现了最好的区分。CA-125水平下降超过7倍的14例患者中有8例（58%）保持无病状态，而36例患者中有3例（9%）下降较少（P = .0005）。在化疗的第一个月CA-125水平的变化可能表明哪些患者应该提供替代或对症治疗，哪些应该继续目前可用的毒性化疗。
The prognostic value of serum CA-125 measurements was assessed in 54 patients with advanced ovarian adenocarcinoma. All patients received a minimum of two courses of carboplatin as part of the North Thames Cooperative Group trial. With a minimum follow-up of 6 months, 37 patients (69%) have clinical evidence of progressive disease and 28 have died. The absolute prechemotherapy level of CA-125 was of no value in predicting which patients would develop progressive disease. However, the change in CA-125 levels from before chemotherapy to 1 month later, after one course of carboplatin, could be used to divide patients into different prognostic groups. The best discrimination was found by dividing the patients into those who showed a greater than sevenfold decrease in CA-125 levels and those who showed a smaller change. Eight of 14 (58%) patients with a greater than sevenfold decrease in CA-125 levels remain disease-free compared with three of 36 (9%) patients with a lesser fall (P = .0005). The change in CA-125 levels during the first month of chemotherapy may indicate which patients should be offered alternative or symptomatic therapy and which should continue with the currently available toxic chemotherapy.